Wednesday, August 09, 2017 3:03:50 AM
Clearly Odidi stupidity is becoming common sense; forget about a partner for rexista, or for anything else...this is how I read Della Penna resignation.
Odidi likely thinks to survive with ATM until FDA decision...which from a strategic point of view is the second worst after dilution at current prices.
He is running out of options.
Della Penna leaving means he doesn't believe anymore in the project; Odidi is crashing the reputation of this company besides crashing our savings.
It really was Beyond my reach that Rexista would have been soooo important for the company future; looks like we are a single product company.
I believe from now on Odidi equals stay away within the financial community following biotechs.
Recent IPCI News
- Suspension de la négociation par l'Organisme canadien de réglementation des investissements - IPCI • PR Newswire (Canada) • 03/06/2024 12:55:00 PM
- Canadian Investment Regulatory Organization Trading Halt - IPCI • PR Newswire (Canada) • 03/06/2024 12:51:00 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM